Dosing and uses of Polymyxin B ophthalmic
Adult dosage forms and strengths
polymyxin B/trimethoprim
ophthalmic solution
- 10,000units/1mg/1mL (10mL)
Conjunctivitis/Blepharoconjunctivitis
1 drop in affected eye(s) q3hr for 7-10 days; not to exceed 6 drops/day in each eye treated
Pediatric dosage forms and strengths
ophthalmic solution
- 10,000units/1mg/1mL (10mL)
Conjunctivitis/Blepharoconjunctivitis
<2 months: Safety and efficacy not established
>2 months: 1 drop in affected eye(s) q3hr for 7-10 days; not to exceed 6 drops/day in each eye treated
Polymyxin B ophthalmic adverse (side) effects
Frequency not defined
Blurry vision
Hypersensitivity (including lid edema, itching, increased redness, tearing, and circumocular rash)
Local irritation (including increased redness, burning, stinging, and itching)
Warnings
Contraindications
Minor ocular irritation; hypersensitivity to any components of product
Pregnancy and lactation
Pregnancy category: C
Lactation: Unknown whether drug is excreted into breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Polymyxin B ophthalmic
Mechanism of action
Bactericidal; causes leakage of bacterial membrane by binding to phospholipids
